Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemdisiran in atypical hemolytic uremic syndrome
NCT03303313Phase 2Withdrawn
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Sep 2017
- Primary completion
- Sep 2018
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 10
01
Overview
A Phase 2 trial of cemdisiran in atypical hemolytic uremic syndrome (aHUS), sponsored by Alnylam Pharmaceuticals. Planned start Sep 2017; status: withdrawn.
02
Drugs
cemdisiran
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on NCT03303313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03303313.